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National Heart and Lung Institute, Imperial College London, United KingdomMetabolic stress, chronic vascular injury and cellular apoptosis are include either proteolytic cleavage or the budding off of membrane mi-
considered as instrumentally connected in the pathogenesis of athero-
sclerosis and diabetes (Gistera and Hansson, 2017). The work from
Mattisson et al. (Mattisson et al., 2017) sheds light on this potentially
important pathway linking cell-mediated death and cardiovascular out-
comes. The study spans translational science, fromdescribing an elegant
laboratory technique using Fas ligand to induce apoptosis in peripheral
blood mononuclear cells and demonstrating release of TNF receptor 1
(TNFR-1), TNF-related apoptosis-inducing ligand receptor 2 (TRAILR-2)
and Fas, to studying the cell death receptor plasma levels in a large
well-characterized prospective population.
The initial experiment demonstrated the link between ligand-
induced apoptosis in cells, and the release of soluble receptors for Fas,
TNFR-1 and TRAILR-2 in vitro, thus justifying the future measurement
of levels of soluble receptors as clinical biomarkers relating to apoptosis.
The authors took the study forward in a subset of the Malmo Diet
and Cancer Study (Berglund et al., 1993), with an impressive follow
up period. This part of the study demonstrated that several cardiovascu-
lar classical risk factors (age, high body mass index, smoking and
hypertension) as well as high triglycerides and low levels of high
density lipoprotein, correlated with the studied markers of death
receptor-activated apoptosis. Furthermore, the highest tertiles for all
three soluble cellular death markers predicted which patients would
go on to develop diabetes, with TRAILR-2 having an independent
association after correction for other risk factors. In addition, patients
with known diabetes exhibited raised levels of markers of receptor-
activated apoptosis. Aside frompredicting incident diabetes, the highest
levels of TRAILR-2 also independently predicted future cardiovascular
death, incident myocardial infarction and stroke.
It has become clear that metabolic risk factors and other exogenous
causes of cellular stress lead to detrimental clinical events via multiple
pathways (Ceriello and Motz, 2004). This paper shows that in vitro
cellular stress on peripheral blood mononuclear cells and a pancreatic
beta cell line leads to the release of soluble death receptors. The mech-
anism for death receptor release remains to be determined, but couldDOI of original article: https://doi.org/10.1016/j.ebiom.2017.11.023.
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Although the mechanistic work in vitro demonstrates a clear link
between the death receptors and apoptosis, and the clinical study
demonstrates an association with cardiovascular outcomes, a causal
link cannot be conclusively proved. Moreover, presently we cannot be
sure what cells released the death receptors into the clinical sample
plasma – although, if microparticle formation is involved, it may be pos-
sible in due course to deﬁne their origin by dual staining with lineage
markers. That said, the value of having a biomarker that may indicate
whether a risk factor has induced cellular damage or not, is strikingly
clear. This may well provide a method of validating difﬁcult to establish
risk factors such as smoking, and may aid in the enrolment of patients
for randomized controlled studies. Rather than just rely on reported
classical risk factors, onemay choose to measure soluble death receptor
levels as entry criteria for prospective studies requiring patients at high
risk of cardiovascular outcomes. In addition, the presence of high death
receptor levels could aid in the selection of high risk patient populations
for novel drug therapies (Ridker et al., 2017), and in particular for
therapies that target the ‘response to injury’ pathway (the response to
cellular injury caused by metabolic or oxidative stress leading to
pathology including atherosclerosis), such as with immunization
(Grasset et al., 2015).
In non-diabetics, levels of these receptors, in particular TRAILR-2,were
associated with the development of diabetes on follow-up. This gives
some plausible support to the controversial notion of loss of beta-cells
in diabetes being a consequence of metabolic stress inducing cell-driven
apoptosis (Halban et al., 2014). There is further value here in suggesting
thatmeasuring TRAILR-2 (if conﬁrmed in other studies)may aid in the se-
lection of patients for diabetic preventionmeasures, such as dietary inter-
ventions, or even novel drugs thatmay aim to preserve beta-cell function.
The authors also undertook a genome-wide association study using
existing databases, and demonstrated a few links with single nucleotide
polymorphisms. However, the genetic polymorphisms linked to plasma
levels of soluble death receptors seem to have a limited effect on cardio-
vascular risk. Therefore, it is likely that the levels of soluble death recep-
tors, although beingpartially dependent on genetics, are unlikely to play
a causal role in the development of cardiovascular disease. Nonetheless,
they can serve as useful biomarkers of disease status, rather than thera-
peutic targets in themselves.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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development of atherosclerosis. For example, the accumulation of
lipoprotein-derived lipids in the artery wall may cause injury and
drive apoptosis, but the process is likely to be policed by the humoral
immune system, therefore preventing a vicious cycle of further injury
and cell death (Khamis et al., 2016;Wang et al., 2016). The levels of sol-
uble cell death receptors may have some correlation with the robust-
ness of these host defenses, and this could present a further avenue
for study. The potential dynamism of levels of the soluble receptors
also needs to be established, to elucidate for example if levels alter
with secondary cardiovascular prevention medications.
It is clear from this work that there may be a role for measuring sol-
uble death-receptor levels to sub-select patients at risk of diabetes and
cardiovascular disease, and target them for early intervention as well
as novel treatments. Once theseﬁndings are conﬁrmed in other cohorts,
some of the receptor levels may also ﬁnd themselves in risk stratiﬁca-
tion matrices that select patients for aggressive cardiovascular and dia-
betes prevention measures, as well as permitting monitoring of the
efﬁcacy of these interventions.
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